Ensysce Biosciences Q4 net loss narrows to $2.8 mln

Reuters05:02

<a href="https://laohu8.com/S/ENSC">Ensysce Biosciences</a> Q4 net loss narrows to $2.8 mln

Overview

US clinical-stage pharma reported Q4 net loss narrowed to $2.8 mln
In 2025, company advanced PF614 to Phase 3 trial and PF614-MPAR under FDA Breakthrough Therapy
Q4 R&D expenses fell slightly

Outlook

Company expects continued losses as R&D efforts toward regulatory approvals progress
Ensysce advancing PF614 toward regulatory submission and potential commercialization
Company pursuing accelerated development and market entry for PF614-MPAR with FDA support

Result Drivers

CLINICAL ADVANCEMENT - Increased external R&D costs in 2025, driven by PF614 and PF614-MPAR clinical and pre-clinical programs
GRANT FUNDING - Federal grant funding rose in Q4, supporting research activities for OUD and MPAR programs

Company press release: ID:nACSYV2NNa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Net Income		-$2.8 mln

Analyst Coverage

Wall Street's median 12-month price target for Ensysce Biosciences Inc is $25.23, about 4,682% above its March 27 closing price of $0.53

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623124321?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623124321","market":"us","top_or_hot":-1,"title":"Ensysce Biosciences Q4 net loss narrows to $2.8 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ENSC\">Ensysce Biosciences</a> Q4 net loss narrows to $2.8 mln</title></head><body><p><span>Overview</span></p><ul><li><p>US clinical-stage pharma reported Q4 net loss narrowed to $2.8 mln</p></li><li><p>In 2025, company advanced PF614 to Phase 3 trial and PF614-MPAR under FDA Breakthrough Therapy</p></li><li><p>Q4 R&amp;D expenses fell slightly</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects continued losses as R&amp;D efforts toward regulatory approvals progress</p></li><li><p>Ensysce advancing PF614 toward regulatory submission and potential commercialization</p></li><li><p>Company pursuing accelerated development and market entry for PF614-MPAR with FDA support</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CLINICAL ADVANCEMENT - Increased external R&amp;D costs in 2025, driven by PF614 and PF614-MPAR clinical and pre-clinical programs</p></li><li><p>GRANT FUNDING - Federal grant funding rose in Q4, supporting research activities for OUD and MPAR programs</p></li></ul><p>Company press release: <span>ID:nACSYV2NNa</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$2.8 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/ENSCW\">Ensysce Biosciences</a> Inc is $25.23, about 4,682% above its March 27 closing price of $0.53</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ensysce Biosciences Q4 net loss narrows to $2.8 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnsysce Biosciences Q4 net loss narrows to $2.8 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-31 05:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ENSC\">Ensysce Biosciences</a> Q4 net loss narrows to $2.8 mln</title></head><body><p><span>Overview</span></p><ul><li><p>US clinical-stage pharma reported Q4 net loss narrowed to $2.8 mln</p></li><li><p>In 2025, company advanced PF614 to Phase 3 trial and PF614-MPAR under FDA Breakthrough Therapy</p></li><li><p>Q4 R&amp;D expenses fell slightly</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects continued losses as R&amp;D efforts toward regulatory approvals progress</p></li><li><p>Ensysce advancing PF614 toward regulatory submission and potential commercialization</p></li><li><p>Company pursuing accelerated development and market entry for PF614-MPAR with FDA support</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CLINICAL ADVANCEMENT - Increased external R&amp;D costs in 2025, driven by PF614 and PF614-MPAR clinical and pre-clinical programs</p></li><li><p>GRANT FUNDING - Federal grant funding rose in Q4, supporting research activities for OUD and MPAR programs</p></li></ul><p>Company press release: <span>ID:nACSYV2NNa</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$2.8 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/ENSCW\">Ensysce Biosciences</a> Inc is $25.23, about 4,682% above its March 27 closing price of $0.53</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nL1N40I10Z:1","article_id":"2623124321","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623124321","pubTimestamp":1774904526,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ensysce Biosciences Q4 net loss narrows to $2.8 mlnOverviewUS clinical-stage pharma reported Q4 net loss narrowed to $2.8 mlnIn 2025, company advanced PF614 to Phase 3 trial and PF614-MPAR under FDA B","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ENSC":"Ensysce Biosciences Inc."},"translate_title":"Ensysce Biosciences第四季度净亏损收窄至280万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENSC":0.9},"content_text":"Ensysce Biosciences Q4 net loss narrows to $2.8 mlnOverviewUS clinical-stage pharma reported Q4 net loss narrowed to $2.8 mlnIn 2025, company advanced PF614 to Phase 3 trial and PF614-MPAR under FDA Breakthrough TherapyQ4 R&D expenses fell slightlyOutlookCompany expects continued losses as R&D efforts toward regulatory approvals progressEnsysce advancing PF614 toward regulatory submission and potential commercializationCompany pursuing accelerated development and market entry for PF614-MPAR with FDA supportResult DriversCLINICAL ADVANCEMENT - Increased external R&D costs in 2025, driven by PF614 and PF614-MPAR clinical and pre-clinical programsGRANT FUNDING - Federal grant funding rose in Q4, supporting research activities for OUD and MPAR programsCompany press release: ID:nACSYV2NNaKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Net Income-$2.8 mlnAnalyst CoverageWall Street's median 12-month price target for Ensysce Biosciences Inc is $25.23, about 4,682% above its March 27 closing price of $0.53For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623124321","isCrawlerRequest":true}